GlassScriptPhysician profile
Amitoz S Manhas
NPI 1033382866
$827.91
in general payments reported to CMS, 2019-2025
19 companies · $53.10 in 2025
The $53.10 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.66 · 2021: $14.92 · 2022: $116 · 2023: $254 · 2024: $308 · 2025: $53.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $615.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $146.25 | 2022-2025 | |
| Depuy Synthes Sales INC. | $81.66 | 2019 | |
| Kls-Martin L.P. | $81.51 | 2024 | |
| Ucb, INC. | $77.01 | 2023-2024 | Rystiggo |
| Acadia Pharmaceuticals INC | $54.94 | 2024 | Nuplazid |
| Eisai INC. | $49.48 | 2024 | |
| Argenx US, INC. | $49.18 | 2023 | Vyvgart Hytrulo |
| Neurelis, INC. | $34.88 | 2023 | Valtoco |
| Lundbeck LLC | $34.22 | 2024 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $30.07 | 2023 | Austedo Xr |
| Medtronic, INC. | $30.03 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.49 | 2024 | |
| Alnylam Pharmaceuticals INC. | $23.78 | 2025 | Amvuttra |
| Tanabe Pharma America, INC. | $23.77 | 2023 | |
| Integra Lifesciences Corporation | $20.47 | 2023 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Certas |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $18.13 | 2022 | |
| Boston Scientific Corporation | $16.70 | 2023 | |
| Amneal Pharmaceuticals LLC | $16.42 | 2022 | |
| Lilly USA, LLC | $14.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amitoz Manhas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.